论文部分内容阅读
目的观察重组人Kunitz型蛋白酶抑制剂的变异体(KD/APP var)对实验性大鼠急性坏死性胰腺炎(acutenecrotizing pancreatitis,ANP)的治疗作用。方法采用牛磺胆酸钠逆行注入大鼠胰胆管内诱导ANP模型,观察重组人KD/APPvar大鼠血清淀粉酶(AMS)、脂肪酶(LPS)影响及胰腺组织病理变化。结果与模型组比较,重组人KD/APP var治疗组可明显降低急性胰腺炎大鼠淀粉酶、脂肪酶的活性,且使胰腺的病理变化减轻。结论重组人KD/APP var早期给药可显著减轻胰腺高分泌状态,对大鼠急性胰腺炎具有治疗作用。
Objective To observe the therapeutic effect of recombinant human Kunitz protease inhibitor (KD / APP var) on experimental acute necrotizing pancreatitis (ANP) in rats. Methods ANP model was induced by retrograde injection of sodium taurocholate into the pancreaticobiliary tract of rats, and the effects of serum amylase (AMS), lipase (LPS) and pathological changes of pancreatic tissue were observed. Results Compared with the model group, recombinant human KD / APP var treatment group could significantly reduce the activity of amylase and lipase in rats with acute pancreatitis and alleviate the pathological changes of the pancreas. Conclusion Early administration of recombinant human KD / APP var can significantly alleviate the pancreatic hypersecretion state and have a therapeutic effect on acute pancreatitis in rats.